In summary, high baseline plasma IL-18 is independently associated with increased mortality in patients with ARDS, and patients with high plasma IL-18 at baseline had reduced 28-day mortality when randomised to simvastatin. The gene discussed is IL18; the disease is acute respiratory distress syndrome.